Veracity Capital LLC Increases Stock Position in Eli Lilly and Company (NYSE:LLY)

Veracity Capital LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.9% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,252 shares of the company’s stock after purchasing an additional 93 shares during the period. Eli Lilly and Company accounts for approximately 1.1% of Veracity Capital LLC’s holdings, making the stock its 12th biggest position. Veracity Capital LLC’s holdings in Eli Lilly and Company were worth $2,881,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Lynx Investment Advisory purchased a new stake in Eli Lilly and Company during the second quarter valued at $32,000. LGT Financial Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $36,000. Redmont Wealth Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter valued at about $40,000. Morton Brown Family Wealth LLC lifted its holdings in shares of Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after acquiring an additional 15 shares during the last quarter. Finally, Cedar Mountain Advisors LLC grew its position in Eli Lilly and Company by 53.3% in the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after acquiring an additional 16 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY opened at $917.97 on Friday. The company has a market capitalization of $872.44 billion, a price-to-earnings ratio of 135.19, a PEG ratio of 2.79 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The business’s fifty day simple moving average is $921.21 and its 200-day simple moving average is $858.02.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. On average, equities research analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Truist Financial upped their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Guggenheim increased their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,025.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $986.00.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.